POPULARITY
6 episodes with antitumor
2 episodes with antitumor
3 episodes with antitumor
2 episodes with antitumor
References:Weight loss on GLP-1 receptor agonistsMoiz A, Levett JY, Filion KB, et al. Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Am J Cardiol 2024, 222:121-130.Highlights: On average, weight loss on semaglutide (Ozempic) is approximately 15% of body weight.Gastrointestinal adverse effects of GLP-1 receptor agonistsSodhi M, Rezaeianzadeh R, Kezouh A, Etminan M. Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss. JAMA 2023.Nutrient Density and Satiety:Drewnowski, A.. Concept of a nutritious food: toward a nutrient density score. The American Journal of Clinical Nutrition 2005. Nutrient-dense foods like greens and beans have been shown to promote satiety, support weight loss, and provide essential micronutrients.Highlights: Nutrient-dense foods can naturally regulate appetite and reduce caloric intake without sacrificing nutrition.Anti-Angiogenic Effects of Vegetables and Mushrooms:Li WW, Li VW, Hutnik M, Chiou AS. Tumor angiogenesis as a target for dietary cancer prevention. J Oncol 2012, 2012:879623. Certain foods, like cruciferous vegetables and green tea, have anti-angiogenic properties that not only combat tumor growth.Corvera S, Solivan-Rivera J, Yang Loureiro Z. Angiogenesis in adipose tissue and obesity. Angiogenesis 2022, 25:439-453.Cao QZ, Lin ZB. Antitumor and anti-angiogenic activity of Ganoderma lucidum polysaccharides peptide. Acta pharmacologica Sinica 2004, 25:833-838.Highlights: Anti-angiogenic foods limit blood vessel growth in fat cells, aiding in long-term weight management.Role of Fiber in Appetite Suppression:Slavin, JL. Dietary fiber and body weight. Nutrition. 2005. High-fiber foods, such as beans and greens, slow digestion, lower postprandial glucose levels, and enhance satiety, contributing to sustainable weight loss.McRorie JW, Jr., McKeown NM. Understanding the Physics of Functional Fibers in the Gastrointestinal Tract: An Evidence-Based Approach to Resolving Enduring Misconceptions about Insoluble and Soluble Fiber. J Acad Nutr Diet 2017, 117:251-264.Highlights: Fiber promotes healthy gut microbiota, which indirectly regulates appetite, and viscous fiber directly regulates appetite by slowing breakdown of macronutrients.Green Tea and Weight Regulation:Neyestani TR, Nikooyeh B. A comprehensive overview on the effects of green tea on anthropometric measures, blood pressure, glycemic and lipidemic status: An umbrella review and meta meta-analysis study. Nutr Metab Cardiovasc Dis 2022, 32:2026-2040. Green tea's catechins and mild caffeine content have been shown to modestly increase fat oxidation and support metabolic health.Highlights: Green tea is a natural complement to weight-loss strategies.Nut Consumption and Caloric Absorption:Tindall AM, Petersen KS, Lamendella R, et al. Tree Nut Consumption and Adipose Tissue Mass: Mechanisms of Action. Curr Dev Nutr 2018, 2:nzy069.Highlights: Whole nuts, not oils, reduce caloric intake without compromising satisfaction.
Featuring a slide presentation and related discussion from Dr Joshua Richter, including the following topics: Similarities and differences between the cellular targets and mechanisms of action of BCMA- and non-BCMA-directed bispecific antibodies for multiple myeloma (MM) (0:00) Antitumor activity observed with teclistamab and elranatamab for relapsed/refractory MM (3:46) Published findings with investigational anti-BCMA bispecific antibodies such as linvoseltamab and alnuctamab for pretreated MM (12:40) Efficacy and safety of approved and investigational non-BCMA-targeted bispecific antibodies in patients with heavily pretreated MM (16:26) Early data with bispecific antibodies in combination with other systemic therapies for MM (22:55) Spectrum, incidence, severity and timing of cytokine release syndrome, neurotoxicity and other adverse events with BCMA- and non-BCMA-targeted bispecific antibodies (26:39) CME information and select publications
Featuring a slide presentation and related discussion from Dr Kanwal Raghav, including the following topics: Prevalence of HER2 alterations among patients with advanced gastrointestinal tumors beyond gastroesophageal cancer (0:00) Dual HER2 inhibition in the treatment of HER2-amplified colorectal cancer (CRC) (4:56) Efficacy and tolerability of the antibody-drug conjugate trastuzumab deruxtecan (T-DXd) for patients with HER2-expressing metastatic CRC (8:52) Activity and safety of the novel bispecific antibody zanidatamab for previously treated HER2-amplified biliary tract cancer (BTC) (14:11) Key findings with tucatinib/trastuzumab for previously treated HER2-positive BTC (21:56) Antitumor activity observed with T-DXd in patients with BTC with HER2 mutations in the Phase II DESTINY-PanTumor02 trial (23:39) CME information and select publications
Featuring perspectives from Dr Melissa Johnson, including the following topics: Role of biomarker testing in optimal selection of first-line therapy for patients with non-small cell lung cancer (NSCLC) (0:00) Efficacy and safety with datopotamab deruxtecan for previously treated NSCLC (15:45) Antitumor activity with and current status of CEACAM5-targeted therapy for relapsed NSCLC (30:24) Evolution of drug development and clinical research (37:56) Key findings with sacituzumab govitecan for NSCLC (41:59) Telisotuzumab vedotin for patients with NSCLC and MET expression (48:44) Recent findings with tumor treating fields for metastatic NSCLC after disease progression on platinum-based therapy (50:49) Other novel antibody-drug conjugates under investigation for NSCLC (55:26) Case: A woman in her mid 50s with recurrent extensive-stage small cell lung cancer who developed pneumonitis on ifinatamab deruxtecan (59:05) Case: A woman in her early 60s with complete response to dose-reduced patritumab deruxtecan (1:00:15) CME information and select publications
The relentless search for effective cancer therapies has led to numerous breakthroughs in drug discovery and development. Advancements have emerged in recent years through the promising avenue of combination therapy, where two or more drugs are used synergistically to enhance their collective therapeutic effect. This strategy has shown significant potential in overcoming drug resistance, reducing side effects, and improving patient survival rates. In a new study, researchers Thomas M. Cardillo, Maria B. Zalath, Roberto Arrojo, Robert M. Sharkey, Serengulam V. Govindan, Chien-Hsing Chang, and David M. Goldenberg from Gilead Sciences and the Center for Molecular Medicine and Immunology demonstrated the significant antitumor effects of Sacituzumab govitecan, an anti-Trop-2-SN-38 antibody-drug conjugate, in combination with platinum-based chemotherapy. On February 22, 2024, their research paper was published in Oncotarget, entitled, “Sacituzumab govitecan plus platinum-based chemotherapy mediates significant antitumor effects in triple-negative breast, urinary bladder, and small-cell lung carcinomas.” Full blog - https://www.oncotarget.org/2024/03/14/antitumor-effects-of-sacituzumab-govitecan-plus-platinum-based-chemotherapy/ Paper DOI - https://doi.org/10.18632/oncotarget.28559 Correspondence to - Thomas M. Cardillo - Thomas.Cardillo1@Gilead.com Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28559 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, sacituzumab govitecan, Trop-2, SN-38, carboplatin, cisplatin About Oncotarget Oncotarget is an open-access, peer-reviewed journal that has published primarily oncology-focused research papers since 2010. These papers are available to readers (at no cost and free of subscription barriers) in a continuous publishing format at Oncotarget.com. Oncotarget is indexed and archived by PubMed/Medline, PubMed Central, Scopus, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science). Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957
“The search for daunorubicin's sister really led to this discovery of doxorubicin, which is an analog with much greater activity. The discovery of doxorubicin can be coined kind of as, ‘one of the best drugs born in Milan, Italy.' And after that, a few analogs were developed and tested, and two that we currently use today, are idarubicin and epirubicin,” Puja Patel, PharmD, BCOP, clinical oncology pharmacist at the Delnor Hospital Northwestern Medicine Cancer Center in Geneva, IL, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a discussion about anthracyclines and other antitumor antibiotics. This episode is part of a series about drug classes, which we'll include a link to in the episode notes. You can earn free NCPD contact hours after listening to this episode and completing the evaluation linked below. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 0.75 contact hours of nursing continuing professional development (NCPD), which may be applied to the nursing practice, oncology nursing practice, symptom management, palliative care, supportive care, or treatment ILNA categories, by listening to the full recording and completing an evaluation at myoutcomes.ons.org by January 26, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of NCPD by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: The learner will report an increase in knowledge of anthracyclines and antitumor antibiotics. Episode Notes Complete this evaluation for free NCPD. Oncology Nursing Podcast: Pharmacology 101 series ONS Voice oncology drug reference sheets IV Cancer Treatment Education Sheets ONS Voice articles: The Evidence Is Building for ACE Inhibitors in Anthracycline-Associated Cardiotoxicity Outpatient Oncology Drug Series: Doxorubicin Is the Infamous Red Devil Clinical Journal of Oncology Nursing articles: Nursing Alchemy: Transforming R-CHOP Information Into Essentials Dyspnea: Common Side Effect Cardiac Toxicity: Using Angiotensin-Converting Enzyme Inhibitors to Prevent Anthracycline-Induced Left Ventricular Dysfunction and Cardiomyopathy Oncology Nursing Forum article: Symptom Clusters in Lymphoma Survivors Before, During, and After Chemotherapy: A Prospective Study ONS Huddle Card: Antitumor Antibiotics Additional healthcare professional resources: Blindspot: Hidden Biases of Good People Harvard University Implicit Association Test OncoPharm Podcast ASCO Education Podcast Additional patient resources: National Comprehensive Cancer Network patient resources National Comprehensive Cancer Network patient webinars National Cancer Institute resources for patients To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast Club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From Today's Episode “Anthracyclines are kind of categorized as topoisomerase II inhibitors, and these agents are very powerful in that they have—it's really like three drugs in one—they have various mechanisms.” TS 3:55 “We need to create a stable environment, and so we actually cut one of the cords, and that's exactly what topoisomerase is doing. It's cutting one of the DNA strands. And in this case, it's cutting two strands, and that's why it's called topoisomerase II, so it's cutting both of the strands. It's cutting the DNA, releasing some of that tension, allowing for replication, and then rejoining that portion. So, it's a very important enzyme, and it'll go about doing this for the entire strand of DNA.” TS 4:50 “The other second mechanism is kind of the effect on DNA. So, you'll come across reading the term ‘DNA intercalation.' So, what does that word mean? When you take the word ‘intercalate,' the definition of it means ‘intrusive inserting of something in an existing series or sequence.' The analogy that I could think of here is simple: It's thinking about too many passengers squeezing in the backseat of your car. There could be safety issues, there's weight issues, there's instability maybe while driving. And that's what this doxorubicin is doing. It's sliding right in between the base pairs of the DNA double helix, destroying hydrogen bonds between those two bases, which then change the shape of that double helix. And by changing the shape, topoisomerase II, which we just talked about, can no longer go in and bind to DNA. It can't relax that super coil. And so, DNA synthesis doesn't happen.” TS 6:02 “So, the main toxicity that our listeners might be familiar with is cardiotoxicity. And also with cardiotoxicity, breaking it down a little bit, there's an onset that occurs during treatment or even years to decades, and that's kind of this delayed cardiotoxicity. Signs and symptoms of acute cardiotoxicity could vary from EKG changes present as tachycardia, tachyarrhythmia. Delayed cardiotoxicity is anything from heart failure to left ventricular ejection fraction decrease.” TS 9:41 “We're worried about heart failure in these patients. So, we might see EKG changes, we might see LVEF [left ventricular ejection fraction] changes, and we're kind of tracking these agents based on what is called cumulative dose tracking or lifetime dose. So, all of these agents have specific lifetime maximums that we need to be aware of.” TS 14:53 “So, smoking, hypertension, diabetes, dyslipidemia, obesity, or you're older in age, or perhaps you have a compromised cardiac function—you're at greater risk for developing these cardiotoxicities. An example that I've had in my clinic is I've identified some of these patients that have these risk factors, and we go into a little bit more aggressive monitoring for the echocardiogram or MUGA [multigated acquisition]. And when we put in those orders, we often get denials from insurance. We submit the guidelines in, kind of, appeals to help those patients kind of proactively realize if we're putting them in a greater cardiac risk.” TS 15:47 “One of the biggest things is for nurses to kind of look over their policies for administration for vesicants and specifically checking blood return for these agents, because many of them are given, you know, IV push. So, checking blood return every 2–5 ml is really important to make sure that you are in the right space. And then these agents, some of them can also be given continuously. So, you're thinking about, first of all, you should have a central line in for these agents because they're vesicants. But if it's being given continuous, there is something that's called anthracycline streaking, and it's not the same as an extravasation. So, I think being able to decipher the difference between the two is really, kind of, comes with experience.” TS 20:36 “I think awareness is really essential. And thankfully, you know, thankfully or not, I guess, you were with the patient for this entire time, right? Because you're pushing every 2–5 ml, you're checking. So, it's a very kind of intimate experience in and of itself. So, I think just being very vigilant is very important.” TS 22:24 “So, to talk about bleomycin here, for example, kinetically, two-thirds of this drug is eliminated renally. And so, we would think that there would need to be renal adjustments if there's renal changes. So, for creatinine clearance greater than 50, there are no renal dose adjustments. But after that, every 10 ml per minute decrease in GFR [glomerular filtration rate], there are dose reductions that are required. And this drug, in particular, has a lot of gradations in terms of renal dysfunction that I've seen.” TS 27:30 “Thinking about bleomycin, it's IV over 10 minutes, and you want to think about the lifetime maximum dose. So, when you are working up your patient, that's something to kind of think about. Dactinomycin is highly emetogenic, so making sure that there's antibiotics on board. It's also a vesicant, so thinking about vesicants precautions. Cold compresses is how you would help treat that if there is an extravasation.” TS 33:14 “I think trust is the foundation oncology really because we are asking our patients to do so many things outside of our infusion center, picking up medications, taking medications, calling us about signs and symptoms, going and getting all these imaging know. So, if there isn't that foundation of trust, having this perfect curative treatment plan may be more challenging to really be carried out.” TS 38:06 “We've developed these very powerful agents, and they're non–cell specific. So, I think the next step would be, how can we reformulate them to make them less toxic and provide more of a targeted approach? And so, perhaps an antibody-drug conjugate that is specifically attacking the lymphoma or the breast cell can deliver this chemotherapy with a cytotoxic payload is there in the horizon.” TS 39:07 “I think the misconception that ‘I will develop heart damage' is really important. Doxorubicin has the infamous name of the red devil, but I think it's important to let your patients know that heart failure increases with cumulative dosing. You know, talking to them about 300 mg/m2 is associated with a 1.5% heart failure risk. Whereas going all the way across to 500 mg/m2, now you're looking at 6%–20% probability of developing heart failure.” TS 42:30 “I think taking the time and understanding the literature. Typically, we don't start these agents with LVEF less than 50–55. There's some great review articles in JCO [Journal of Clinical Oncology] that kind of define what cardiomyopathy decrease looks like and decreases in LVEF over 10% to a value below the institutional limit of normal, I think, is a nice point to have as a value, a number to kind of work with.” TS 43:53 “Working with your nurse educator and leader to help achieve OCN®, oncology certified nurse, certification is really important. And I think live simulated experiences are really beneficial, maybe even looking at extravasations or having an infusion-related reaction, because here in the acute setting, we're really kind of in this like responsive mode. But if we practice, we can respond more deliberately and more calmly.” TS 45:05
In this episode, we review the high-yield topic of Antitumor Antibiotics from the Oncology section. Follow Medbullets on social media: Facebook: www.facebook.com/medbullets Instagram: www.instagram.com/medbulletsofficial Twitter: www.twitter.com/medbullets --- Send in a voice message: https://podcasters.spotify.com/pod/show/medbulletsstep1/message
Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2023.03.29.534690v1?rss=1 Authors: Islam, A., Chen, X.-C., Weng, C.-W., Chen, C.-Y., Wang, C.-W., Chen, M.-K., Tikhomirov, A. S., Shchekotikhin, A. E., Chueh, P. J. Abstract: The antibiotic heliomycin (resistomycin), which is generated from Streptomyces resistomycificus, has multiple activities, including anticancer effects. Heliomycin was first described in the 1960s, but its clinical applications have been hindered by extremely low solubility. A series of 4-aminomethyl derivatives of heliomycin were synthesized to increase water solubility; studies showed that they had anti-proliferative effects, but the drug targets remained unknown. In this study, we conducted cellular thermal shift assays and molecular docking simulations to identify and validate the intracellular targets of heliomycin and its water-soluble derivative, 4-(dimethylaminomethyl)heliomycin (designated compound 4-dmH), in p53-functional SAS and p53-mutated HSC-3 oral cancer cells. Consistent with our in silico studies, our cellular thermal shift assays (CETSA) revealed that, in addition to SIRT1, the water-soluble 4-dmH preferentially targeted a tumor-associated NADH oxidase called tNOX or ENOX2. The direct binding of 4-dmH to tNOX inhibited the activity of tNOX and enhanced its ubiquitin-proteasomal protein degradation in both SAS and HSC-3 cells. Moreover, the inhibition of tNOX by 4-dmH decreased the oxidation of NADH to NAD+ which diminished NAD+-dependent SIRT1 deacetylase activity, ultimately inducing apoptosis and significant cytotoxicity in both cell types. We also observed that tNOX and SIRT1 were both upregulated in tumor tissues of oral cancer patients compared to adjacent normal tissues, suggesting their clinical relevance. Finally, the better therapeutic efficacy of 4-dmH was confirmed in tumor-bearing mice, which showed greater tNOX and SIRT1 downregulation and tumor volume reduction when treated with 4-dmH compared to heliomycin. Taken together, our in vitro and in vivo findings suggest that the multifaceted properties of water-soluble 4-dmH enable it to offer superior antitumor value compared to parental heliomycin, and indicated that it functions through targeting the tNOX-NAD+-SIRT1 axis to induce apoptosis in oral cancer cells. Copy rights belong to original authors. Visit the link for more info Podcast created by Paper Player, LLC
CME credits: 0.25 Valid until: 30-11-2023 Claim your CME credit at https://reachmd.com/programs/cme/innovations-in-the-treatment-of-locally-advanced-squamous-cell-carcinoma-of-head-and-neck-enhancing-antitumor-activity-through-inhibitor-of-apoptosis-protein-antagonism/14129/ There is an unmet clinical need for more durable responses in many patients with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN). Advances in delineating the anti-apoptotic signaling mechanisms are guiding the development of novel therapeutic options for these patients. Join Drs. Kevin Harrington, Barbara Burtness, and Ari Rosenberg as they discuss challenges in treating patients with LA SCCHN and focus on the latest clinical data surrounding an antagonist of inhibitor of apoptosis proteins in this patient population.
A new research paper was published in Oncotarget's Volume 13 on November 2, 2022, entitled, “MK256 is a novel CDK8 inhibitor with potent antitumor activity in AML through downregulation of the STAT pathway.” Acute myeloid leukemia (AML) is the most lethal form of AML due to disease relapse. Cyclin dependent kinase 8 (CDK8) is a serine/threonine kinase that belongs to the family of Cyclin-dependent kinases and is an emerging target for the treatment of AML. MK256, a potent, selective, and orally available CDK8 inhibitor was developed to target AML. In this new study, researchers Jen-Chieh Lee, Shu Liu, Yucheng Wang, You Liang, and David M. Jablons from the University of California San Francisco and Touro University sought to examine the anticancer effect of MK256 on AML. “In CD34+/CD38- leukemia stem cells, we found that MK256 induced differentiation and maturation.” Treatment of MK256 inhibited proliferation of AML cell lines. Further studies of the inhibitory effect suggested that MK256 not only downregulated phosphorylated STAT1(S727) and STAT5(S726), but also lowered mRNA expressions of MCL-1 and CCL2 in AML cell lines. Efficacy of MK256 was shown in MOLM-14 xenograft models, and the inhibitory effect on phosphorylated STAT1(S727) and STAT5(S726) with treatment of MK256 was observed in vivo. Pharmacologic dynamics study of MK256 in MOLM-14 xenograft models showed dose-dependent inhibition of the STAT pathway. Both in vitro and in vivo studies suggested that MK256 could effectively downregulate the STAT pathway. In vitro ADME, pharmacological kinetics, and toxicity of MK256 were profiled to evaluate the drug properties of MK256. “Our results show that MK256 is a novel CDK8 inhibitor with a desirable efficacy and safety profile and has great potential to be a promising drug candidate for AML through regulating the STAT pathway.” DOI: https://doi.org/10.18632/oncotarget.28305 Correspondence to: Jen-Chieh Lee -jenchieh.lee@ucsf.edu, Shu Liu - shu.liu@ucsf.edu Keywords: AML, CDK8, kinase inhibitor, STAT pathway, xenograft Video: https://www.youtube.com/watch?v=8bRgqTg9-c8 About Oncotarget: Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. To learn more about Oncotarget, visit Oncotarget.com and connect with us on social media: Twitter – https://twitter.com/Oncotarget Facebook – https://www.facebook.com/Oncotarget YouTube – www.youtube.com/c/OncotargetYouTube Instagram – https://www.instagram.com/oncotargetjrnl/ LinkedIn – https://www.linkedin.com/company/oncotarget/ Pinterest – https://www.pinterest.com/oncotarget/ LabTube – https://www.labtube.tv/channel/MTY5OA SoundCloud – https://soundcloud.com/oncotarget For media inquiries, please contact: media@impactjournals.com
Go online to PeerView.com/EBJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The discovery of immune checkpoints that regulate immune responses transformed cancer care, and the impact that the new class of immune checkpoint inhibitors (ICIs) has had in oncology cannot be understated. A proportion of patients achieve remarkable and durable responses and improved overall survival with use of the current ICIs. However, there are a number of limitations associated with the current immunotherapies, patient outcomes are still suboptimal, and new options are needed to maximize the potential of cancer immunotherapy as the fourth treatment pillar in oncology. New rational combinations leveraging synergies between old and new checkpoints have emerged, with inhibitory targeting of T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine–based inhibitory motif domains (TIGIT) along with the PD-L1/PD-1 pathway as one potential strategy under extensive investigation across different cancers. To realize the potential of anti-TIGIT checkpoint inhibition, build upon previous advances in cancer immunotherapy, expand into more tumor types and earlier stages of disease, and provide new treatment options in areas of high unmet need to more patients with cancer, it is essential for those involved in the care of patients with solid tumors to become familiar with this novel therapeutic approach and develop competence related to its clinical integration, enabling rapid translation from discovery to the clinic. This educational activity features an expert discussion of the rationale and mechanism of action of agents targeting TIGIT, enhanced with engaging three-dimensional explanations, and provides practical guidance to identify patients most likely to be the best candidates for novel ICI-based treatment approaches. Upon completion of this activity, participants should be better able to: Describe the rationale for use, mechanisms of action, and preclinical and clinical evidence supporting the use of novel ICIs, such as antibodies targeting TIGIT, and synergistic ICI-based combinations showing promise in overcoming the limitations of current immunotherapies and expanding the benefits to more patients with solid tumors, Identify patients who are most likely to be the best candidates for novel ICI-based treatment approaches, including dual-targeted inhibition of TIGIT and anti–PD-L1/PD-1, based on clinical evidence, biomarker status, comorbidities, patient preferences for chemotherapy-free treatment options, and other relevant factors, working collaboratively as a healthcare team.
Go online to PeerView.com/EBJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The discovery of immune checkpoints that regulate immune responses transformed cancer care, and the impact that the new class of immune checkpoint inhibitors (ICIs) has had in oncology cannot be understated. A proportion of patients achieve remarkable and durable responses and improved overall survival with use of the current ICIs. However, there are a number of limitations associated with the current immunotherapies, patient outcomes are still suboptimal, and new options are needed to maximize the potential of cancer immunotherapy as the fourth treatment pillar in oncology. New rational combinations leveraging synergies between old and new checkpoints have emerged, with inhibitory targeting of T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine–based inhibitory motif domains (TIGIT) along with the PD-L1/PD-1 pathway as one potential strategy under extensive investigation across different cancers. To realize the potential of anti-TIGIT checkpoint inhibition, build upon previous advances in cancer immunotherapy, expand into more tumor types and earlier stages of disease, and provide new treatment options in areas of high unmet need to more patients with cancer, it is essential for those involved in the care of patients with solid tumors to become familiar with this novel therapeutic approach and develop competence related to its clinical integration, enabling rapid translation from discovery to the clinic. This educational activity features an expert discussion of the rationale and mechanism of action of agents targeting TIGIT, enhanced with engaging three-dimensional explanations, and provides practical guidance to identify patients most likely to be the best candidates for novel ICI-based treatment approaches. Upon completion of this activity, participants should be better able to: Describe the rationale for use, mechanisms of action, and preclinical and clinical evidence supporting the use of novel ICIs, such as antibodies targeting TIGIT, and synergistic ICI-based combinations showing promise in overcoming the limitations of current immunotherapies and expanding the benefits to more patients with solid tumors, Identify patients who are most likely to be the best candidates for novel ICI-based treatment approaches, including dual-targeted inhibition of TIGIT and anti–PD-L1/PD-1, based on clinical evidence, biomarker status, comorbidities, patient preferences for chemotherapy-free treatment options, and other relevant factors, working collaboratively as a healthcare team.
Go online to PeerView.com/EBJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The discovery of immune checkpoints that regulate immune responses transformed cancer care, and the impact that the new class of immune checkpoint inhibitors (ICIs) has had in oncology cannot be understated. A proportion of patients achieve remarkable and durable responses and improved overall survival with use of the current ICIs. However, there are a number of limitations associated with the current immunotherapies, patient outcomes are still suboptimal, and new options are needed to maximize the potential of cancer immunotherapy as the fourth treatment pillar in oncology. New rational combinations leveraging synergies between old and new checkpoints have emerged, with inhibitory targeting of T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine–based inhibitory motif domains (TIGIT) along with the PD-L1/PD-1 pathway as one potential strategy under extensive investigation across different cancers. To realize the potential of anti-TIGIT checkpoint inhibition, build upon previous advances in cancer immunotherapy, expand into more tumor types and earlier stages of disease, and provide new treatment options in areas of high unmet need to more patients with cancer, it is essential for those involved in the care of patients with solid tumors to become familiar with this novel therapeutic approach and develop competence related to its clinical integration, enabling rapid translation from discovery to the clinic. This educational activity features an expert discussion of the rationale and mechanism of action of agents targeting TIGIT, enhanced with engaging three-dimensional explanations, and provides practical guidance to identify patients most likely to be the best candidates for novel ICI-based treatment approaches. Upon completion of this activity, participants should be better able to: Describe the rationale for use, mechanisms of action, and preclinical and clinical evidence supporting the use of novel ICIs, such as antibodies targeting TIGIT, and synergistic ICI-based combinations showing promise in overcoming the limitations of current immunotherapies and expanding the benefits to more patients with solid tumors, Identify patients who are most likely to be the best candidates for novel ICI-based treatment approaches, including dual-targeted inhibition of TIGIT and anti–PD-L1/PD-1, based on clinical evidence, biomarker status, comorbidities, patient preferences for chemotherapy-free treatment options, and other relevant factors, working collaboratively as a healthcare team.
Go online to PeerView.com/EBJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The discovery of immune checkpoints that regulate immune responses transformed cancer care, and the impact that the new class of immune checkpoint inhibitors (ICIs) has had in oncology cannot be understated. A proportion of patients achieve remarkable and durable responses and improved overall survival with use of the current ICIs. However, there are a number of limitations associated with the current immunotherapies, patient outcomes are still suboptimal, and new options are needed to maximize the potential of cancer immunotherapy as the fourth treatment pillar in oncology. New rational combinations leveraging synergies between old and new checkpoints have emerged, with inhibitory targeting of T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine–based inhibitory motif domains (TIGIT) along with the PD-L1/PD-1 pathway as one potential strategy under extensive investigation across different cancers. To realize the potential of anti-TIGIT checkpoint inhibition, build upon previous advances in cancer immunotherapy, expand into more tumor types and earlier stages of disease, and provide new treatment options in areas of high unmet need to more patients with cancer, it is essential for those involved in the care of patients with solid tumors to become familiar with this novel therapeutic approach and develop competence related to its clinical integration, enabling rapid translation from discovery to the clinic. This educational activity features an expert discussion of the rationale and mechanism of action of agents targeting TIGIT, enhanced with engaging three-dimensional explanations, and provides practical guidance to identify patients most likely to be the best candidates for novel ICI-based treatment approaches. Upon completion of this activity, participants should be better able to: Describe the rationale for use, mechanisms of action, and preclinical and clinical evidence supporting the use of novel ICIs, such as antibodies targeting TIGIT, and synergistic ICI-based combinations showing promise in overcoming the limitations of current immunotherapies and expanding the benefits to more patients with solid tumors, Identify patients who are most likely to be the best candidates for novel ICI-based treatment approaches, including dual-targeted inhibition of TIGIT and anti–PD-L1/PD-1, based on clinical evidence, biomarker status, comorbidities, patient preferences for chemotherapy-free treatment options, and other relevant factors, working collaboratively as a healthcare team.
Go online to PeerView.com/EBJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The discovery of immune checkpoints that regulate immune responses transformed cancer care, and the impact that the new class of immune checkpoint inhibitors (ICIs) has had in oncology cannot be understated. A proportion of patients achieve remarkable and durable responses and improved overall survival with use of the current ICIs. However, there are a number of limitations associated with the current immunotherapies, patient outcomes are still suboptimal, and new options are needed to maximize the potential of cancer immunotherapy as the fourth treatment pillar in oncology. New rational combinations leveraging synergies between old and new checkpoints have emerged, with inhibitory targeting of T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine–based inhibitory motif domains (TIGIT) along with the PD-L1/PD-1 pathway as one potential strategy under extensive investigation across different cancers. To realize the potential of anti-TIGIT checkpoint inhibition, build upon previous advances in cancer immunotherapy, expand into more tumor types and earlier stages of disease, and provide new treatment options in areas of high unmet need to more patients with cancer, it is essential for those involved in the care of patients with solid tumors to become familiar with this novel therapeutic approach and develop competence related to its clinical integration, enabling rapid translation from discovery to the clinic. This educational activity features an expert discussion of the rationale and mechanism of action of agents targeting TIGIT, enhanced with engaging three-dimensional explanations, and provides practical guidance to identify patients most likely to be the best candidates for novel ICI-based treatment approaches. Upon completion of this activity, participants should be better able to: Describe the rationale for use, mechanisms of action, and preclinical and clinical evidence supporting the use of novel ICIs, such as antibodies targeting TIGIT, and synergistic ICI-based combinations showing promise in overcoming the limitations of current immunotherapies and expanding the benefits to more patients with solid tumors, Identify patients who are most likely to be the best candidates for novel ICI-based treatment approaches, including dual-targeted inhibition of TIGIT and anti–PD-L1/PD-1, based on clinical evidence, biomarker status, comorbidities, patient preferences for chemotherapy-free treatment options, and other relevant factors, working collaboratively as a healthcare team.
Go online to PeerView.com/EBJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The discovery of immune checkpoints that regulate immune responses transformed cancer care, and the impact that the new class of immune checkpoint inhibitors (ICIs) has had in oncology cannot be understated. A proportion of patients achieve remarkable and durable responses and improved overall survival with use of the current ICIs. However, there are a number of limitations associated with the current immunotherapies, patient outcomes are still suboptimal, and new options are needed to maximize the potential of cancer immunotherapy as the fourth treatment pillar in oncology. New rational combinations leveraging synergies between old and new checkpoints have emerged, with inhibitory targeting of T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine–based inhibitory motif domains (TIGIT) along with the PD-L1/PD-1 pathway as one potential strategy under extensive investigation across different cancers. To realize the potential of anti-TIGIT checkpoint inhibition, build upon previous advances in cancer immunotherapy, expand into more tumor types and earlier stages of disease, and provide new treatment options in areas of high unmet need to more patients with cancer, it is essential for those involved in the care of patients with solid tumors to become familiar with this novel therapeutic approach and develop competence related to its clinical integration, enabling rapid translation from discovery to the clinic. This educational activity features an expert discussion of the rationale and mechanism of action of agents targeting TIGIT, enhanced with engaging three-dimensional explanations, and provides practical guidance to identify patients most likely to be the best candidates for novel ICI-based treatment approaches. Upon completion of this activity, participants should be better able to: Describe the rationale for use, mechanisms of action, and preclinical and clinical evidence supporting the use of novel ICIs, such as antibodies targeting TIGIT, and synergistic ICI-based combinations showing promise in overcoming the limitations of current immunotherapies and expanding the benefits to more patients with solid tumors, Identify patients who are most likely to be the best candidates for novel ICI-based treatment approaches, including dual-targeted inhibition of TIGIT and anti–PD-L1/PD-1, based on clinical evidence, biomarker status, comorbidities, patient preferences for chemotherapy-free treatment options, and other relevant factors, working collaboratively as a healthcare team.
Go online to PeerView.com/EBJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The discovery of immune checkpoints that regulate immune responses transformed cancer care, and the impact that the new class of immune checkpoint inhibitors (ICIs) has had in oncology cannot be understated. A proportion of patients achieve remarkable and durable responses and improved overall survival with use of the current ICIs. However, there are a number of limitations associated with the current immunotherapies, patient outcomes are still suboptimal, and new options are needed to maximize the potential of cancer immunotherapy as the fourth treatment pillar in oncology. New rational combinations leveraging synergies between old and new checkpoints have emerged, with inhibitory targeting of T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine–based inhibitory motif domains (TIGIT) along with the PD-L1/PD-1 pathway as one potential strategy under extensive investigation across different cancers. To realize the potential of anti-TIGIT checkpoint inhibition, build upon previous advances in cancer immunotherapy, expand into more tumor types and earlier stages of disease, and provide new treatment options in areas of high unmet need to more patients with cancer, it is essential for those involved in the care of patients with solid tumors to become familiar with this novel therapeutic approach and develop competence related to its clinical integration, enabling rapid translation from discovery to the clinic. This educational activity features an expert discussion of the rationale and mechanism of action of agents targeting TIGIT, enhanced with engaging three-dimensional explanations, and provides practical guidance to identify patients most likely to be the best candidates for novel ICI-based treatment approaches. Upon completion of this activity, participants should be better able to: Describe the rationale for use, mechanisms of action, and preclinical and clinical evidence supporting the use of novel ICIs, such as antibodies targeting TIGIT, and synergistic ICI-based combinations showing promise in overcoming the limitations of current immunotherapies and expanding the benefits to more patients with solid tumors, Identify patients who are most likely to be the best candidates for novel ICI-based treatment approaches, including dual-targeted inhibition of TIGIT and anti–PD-L1/PD-1, based on clinical evidence, biomarker status, comorbidities, patient preferences for chemotherapy-free treatment options, and other relevant factors, working collaboratively as a healthcare team.
Go online to PeerView.com/EBJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The discovery of immune checkpoints that regulate immune responses transformed cancer care, and the impact that the new class of immune checkpoint inhibitors (ICIs) has had in oncology cannot be understated. A proportion of patients achieve remarkable and durable responses and improved overall survival with use of the current ICIs. However, there are a number of limitations associated with the current immunotherapies, patient outcomes are still suboptimal, and new options are needed to maximize the potential of cancer immunotherapy as the fourth treatment pillar in oncology. New rational combinations leveraging synergies between old and new checkpoints have emerged, with inhibitory targeting of T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine–based inhibitory motif domains (TIGIT) along with the PD-L1/PD-1 pathway as one potential strategy under extensive investigation across different cancers. To realize the potential of anti-TIGIT checkpoint inhibition, build upon previous advances in cancer immunotherapy, expand into more tumor types and earlier stages of disease, and provide new treatment options in areas of high unmet need to more patients with cancer, it is essential for those involved in the care of patients with solid tumors to become familiar with this novel therapeutic approach and develop competence related to its clinical integration, enabling rapid translation from discovery to the clinic. This educational activity features an expert discussion of the rationale and mechanism of action of agents targeting TIGIT, enhanced with engaging three-dimensional explanations, and provides practical guidance to identify patients most likely to be the best candidates for novel ICI-based treatment approaches. Upon completion of this activity, participants should be better able to: Describe the rationale for use, mechanisms of action, and preclinical and clinical evidence supporting the use of novel ICIs, such as antibodies targeting TIGIT, and synergistic ICI-based combinations showing promise in overcoming the limitations of current immunotherapies and expanding the benefits to more patients with solid tumors, Identify patients who are most likely to be the best candidates for novel ICI-based treatment approaches, including dual-targeted inhibition of TIGIT and anti–PD-L1/PD-1, based on clinical evidence, biomarker status, comorbidities, patient preferences for chemotherapy-free treatment options, and other relevant factors, working collaboratively as a healthcare team.
Go online to PeerView.com/EBJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The discovery of immune checkpoints that regulate immune responses transformed cancer care, and the impact that the new class of immune checkpoint inhibitors (ICIs) has had in oncology cannot be understated. A proportion of patients achieve remarkable and durable responses and improved overall survival with use of the current ICIs. However, there are a number of limitations associated with the current immunotherapies, patient outcomes are still suboptimal, and new options are needed to maximize the potential of cancer immunotherapy as the fourth treatment pillar in oncology. New rational combinations leveraging synergies between old and new checkpoints have emerged, with inhibitory targeting of T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine–based inhibitory motif domains (TIGIT) along with the PD-L1/PD-1 pathway as one potential strategy under extensive investigation across different cancers. To realize the potential of anti-TIGIT checkpoint inhibition, build upon previous advances in cancer immunotherapy, expand into more tumor types and earlier stages of disease, and provide new treatment options in areas of high unmet need to more patients with cancer, it is essential for those involved in the care of patients with solid tumors to become familiar with this novel therapeutic approach and develop competence related to its clinical integration, enabling rapid translation from discovery to the clinic. This educational activity features an expert discussion of the rationale and mechanism of action of agents targeting TIGIT, enhanced with engaging three-dimensional explanations, and provides practical guidance to identify patients most likely to be the best candidates for novel ICI-based treatment approaches. Upon completion of this activity, participants should be better able to: Describe the rationale for use, mechanisms of action, and preclinical and clinical evidence supporting the use of novel ICIs, such as antibodies targeting TIGIT, and synergistic ICI-based combinations showing promise in overcoming the limitations of current immunotherapies and expanding the benefits to more patients with solid tumors, Identify patients who are most likely to be the best candidates for novel ICI-based treatment approaches, including dual-targeted inhibition of TIGIT and anti–PD-L1/PD-1, based on clinical evidence, biomarker status, comorbidities, patient preferences for chemotherapy-free treatment options, and other relevant factors, working collaboratively as a healthcare team.
Go online to PeerView.com/EBJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The discovery of immune checkpoints that regulate immune responses transformed cancer care, and the impact that the new class of immune checkpoint inhibitors (ICIs) has had in oncology cannot be understated. A proportion of patients achieve remarkable and durable responses and improved overall survival with use of the current ICIs. However, there are a number of limitations associated with the current immunotherapies, patient outcomes are still suboptimal, and new options are needed to maximize the potential of cancer immunotherapy as the fourth treatment pillar in oncology. New rational combinations leveraging synergies between old and new checkpoints have emerged, with inhibitory targeting of T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine–based inhibitory motif domains (TIGIT) along with the PD-L1/PD-1 pathway as one potential strategy under extensive investigation across different cancers. To realize the potential of anti-TIGIT checkpoint inhibition, build upon previous advances in cancer immunotherapy, expand into more tumor types and earlier stages of disease, and provide new treatment options in areas of high unmet need to more patients with cancer, it is essential for those involved in the care of patients with solid tumors to become familiar with this novel therapeutic approach and develop competence related to its clinical integration, enabling rapid translation from discovery to the clinic. This educational activity features an expert discussion of the rationale and mechanism of action of agents targeting TIGIT, enhanced with engaging three-dimensional explanations, and provides practical guidance to identify patients most likely to be the best candidates for novel ICI-based treatment approaches. Upon completion of this activity, participants should be better able to: Describe the rationale for use, mechanisms of action, and preclinical and clinical evidence supporting the use of novel ICIs, such as antibodies targeting TIGIT, and synergistic ICI-based combinations showing promise in overcoming the limitations of current immunotherapies and expanding the benefits to more patients with solid tumors, Identify patients who are most likely to be the best candidates for novel ICI-based treatment approaches, including dual-targeted inhibition of TIGIT and anti–PD-L1/PD-1, based on clinical evidence, biomarker status, comorbidities, patient preferences for chemotherapy-free treatment options, and other relevant factors, working collaboratively as a healthcare team.
Featuring an interview with Dr Gregory Riely, including the following topics: EGFR exon 20 insertions in non-small cell lung cancer (NSCLC) (0:00) Antitumor activity, mechanism of action and tolerability of mobocertinib for patients with NSCLC and EGFR exon 20 mutations (4:59) Antitumor activity and tolerability of the EGFR-MET bispecific antibody amivantamab (11:05) Considerations for using real-world data to create synthetic control arms for clinical trials (17:48) Novel investigational agents for and future management of NSCLC with EGFR exon 20 insertions (23:48) CME information and select publications
Most people are aware by now that exercise has positive effects in “healthy” individuals and in patients with cancer. In cancer patients, exercise has been shown to reduce adverse events, improve quality-of-life and respiratory fitness, and even decrease the risk of breast cancer recurrence. These results, and many others, have prompted major national and international cancer organizations to make exercise recommendations. “There also is a growing body of evidence that exercise may directly alter the tumor microenvironment to influence tumor growth, metastasis, and response to anticancer therapies.” However, scientists and researchers have only scratched the surface of understanding the extent of the benefits that are capable of being harnessed by exercise. While research shows that exercise may impact tumors, the exercise prescription needed to induce these beneficial tumor-related outcomes is still unclear. In an effort to better harness the benefits of exercise, researchers from the University of Florida conducted a study on the effects of wheel running in breast cancer mouse models and chemotherapy. Their paper was published as the cover of Oncotarget's Volume 12, Issue 18, and entitled, “Normal tissue and tumor microenvironment adaptations to aerobic exercise enhance doxorubicin anti-tumor efficacy and ameliorate its cardiotoxicity in retired breeder mice.” “The goal of this study was to characterize the exercise prescription by evaluating the aerobic adaptations in both the normal tissue and the tumor microenvironment. Moreover, doxorubicin was used to assess the adjuvant effects of aerobic exercise on chemotherapy efficacy and toxicity.” Full blog - https://www.impactjournals.com/journals/blog/oncotarget/new-study-how-exercise-boosted-chemotherapy-in-mice/ Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28057 DOI - https://doi.org/10.18632/oncotarget.28057 Full text - https://www.oncotarget.com/article/28057/text/ Correspondence to - Zachary R. Wakefield - zwakefield@ufl.edu Keywords - aerobic exercise, breast cancer, hypoxia, doxorubicin, cardiotoxicity About Oncotarget Oncotarget is a bi-weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology. To learn more about Oncotarget, please visit https://www.oncotarget.com or connect with: SoundCloud - https://soundcloud.com/oncotarget Facebook - https://www.facebook.com/Oncotarget/ Twitter - https://twitter.com/oncotarget YouTube - https://www.youtube.com/c/OncotargetYouTube/ LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Oncotarget is published by Impact Journals, LLC please visit https://www.ImpactJournals.com or connect with @ImpactJrnls Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957
Featuring an interview with Dr Kathleen Moore, including the following topics: Optimal treatment duration of bevacizumab in combination with paclitaxel/carboplatin for advanced ovarian cancer (0:00) Phase III PAOLA-1 trial subgroup analysis: Progression-free survival outcomes by disease stage in patients with newly diagnosed, homologous recombination-deficient advanced ovarian cancer (4:44) Efficacy and safety results from the randomized Phase II NEOPEMBROV study assessing neoadjuvant chemotherapy with or without pembrolizumab for patients with advanced high-grade serous carcinoma not eligible for front-line debulking surgery (6:50) Combined analysis of Phase III studies assessing the efficacy and safety of niraparib in patients with ovarian cancer with BRCA mutations (11:28) Rucaparib versus chemotherapy for relapsed ovarian carcinoma with BRCA mutation in the platinum-sensitive subgroup of patients: Results from the Phase III ARIEL4 study (13:45) Clinical activity of olaparib combinations in patients with recurrent PARP inhibitor-resistant cancer: Results from the Phase II CAPRI and EFFORT trials (17:55) Efficacy of the combination of mirvetuximab soravtansine and bevacizumab for platinum-agnostic ovarian cancer (25:34) Results from the Phase III OUTBACK trial comparing adjuvant chemotherapy after chemoradiation therapy to chemoradiation therapy alone for locally advanced cervical cancer (27:55) Clinical data with immunotherapeutic agents for cervical cancer; ongoing Phase III innovaTV 301 study assessing tisotumab vedotin versus chemotherapy for recurrent metastatic cervical cancer (31:14) Role of surveillance in the management of endometrial cancer: Results from the TOTEM study (34:51) Antitumor activity of dostarlimab alone or in combination with a PARP inhibitor for recurrent endometrial carcinoma (36:51) Comparison of health-related quality of life with lenvatinib/pembrolizumab versus chemotherapy for patients with advanced endometrial cancer (39:48) Biomarkers of response to immune checkpoint inhibitors; Results from the TAPUR study of dual HER2-targeted therapy for patients with uterine cancer and ERBB2 or ERBB3 abnormalities (41:17) CME information and select publications
กัญชา สมุนไพรที่อยู่คู่กับมนุษย์มาอย่างช้านาน ทั้งในเรื่องของการใช้เพื่อสันทนาการ และการนำประโยชน์มาใช้ในทางการแพทย์ แล้วกัญชานั้นแบ่งออกเป็นกี่สายพันธุ์ มีข้อดี ข้อเสีย หรือข้อควรระวังในการใช้อย่างไรบ้าง มาติดตามได้ในรายการ Dr.Amp Podcast เรื่องเล่าสุขภาพดี กับ หมอแอมป์ ตอน "กัญชา คุณค่าสมุนไพรจากธรรมชาติ" โดย นพ. ตนุพล วิรุฬหการุญ -ประธานเจ้าหน้าที่ปฏิบัติการ และ ผู้อำนวยการ BDMS Welness Clinic -ผู้อำนวยการ RoyalLife โรงพยาบาลกรุงเทพ -นายกสมาคมแพทย์ฟื้นฟูสุขภาพและส่งเสริมการศึกษาโรคอ้วน กรุงเทพ (BARSO) สามารถค้นหารายชื่อแพทย์ที่ผ่านการอบรมหลักสูตรการใช้กัญชาที่กรมการแพทย์ หรือ กรมการแพทย์แผนไทยและการแพทย์ทางเลือกให้การรับรองได้ที่: http://hemp.fda.moph.go.th/FDA_MARIJUANA/SAS/VISIT_DOCTOR
#therichsolution #motherofprobiotics #natrenconcepts“Anti-carcinogenic and Antitumor properties of selected strains of Bacteria”Join me today at 10:00am CT on Mojo50 Radio. My guest Natasha Trenev, Founder & President of @natrenprobiotics_ and probiotic pioneer. She will speak to the topic of “Anti-carcinogenic and Antitumor properties of selected strains of Bacteria”Here's what you'll learn:*Learn how to stimulate your immune response to have anti-carcinogenic-antitumor effect. *How you can help eliminate the production of toxic, carcinogen or mutagenic compounds from one's daily diet.*Learn what is associated with a resistance to a wide range of age-related diseases including colorectal cancer.Listen @ 10:00am CT on:www.mojo50.comHeart RadioiTunesAppleLive streaming via:YouTube and Facebook:https://www.facebook.com/Therichsolution/https://www.youtube.com/c/therichsolution
Dr Cristina Sánchez, Vice Dean of Research at the School of Biology at the Complutense University in Madrid, is a world renowned molecular biologist specialising in the study of compounds in the cannabis plant as anticancer agents in breast cancer. Cristina has been involved in researching the antitumoral properties of cannabinoids for over twenty years, and played a key role in discovering how THC kills cancer cells while working alongside colleague Professor Manuel Guzmán.These days, while many research groups around the world focussing on isolated or synthetic cannabinoids as potential anticancer drugs, Cristina's group stands out as trying to understand and replicate the experiences of actual patients who are reporting extraordinary results using whole plant cannabis for their cancer.In her paper, 'Appraising the ''entourage effect'': Antitumor action of pure cannabinoid versus a botanical drug preparation in preclinical models of breast cancer,' Sánchez found that in mice at least and across all types of breast cancer, a whole plant cannabis extract was more efficacious and potent than THC alone. As Cristina says: "This is not a hippie fashion or energy from the plant. No, this is science. This is molecules activating and deactivating. So the same thing as for opioids or for any of the drugs that they use."Resources:Appraising the "entourage effect": Antitumor action of a pure cannabinoid versus a botanical drug preparation in preclinical models of breast cancerCannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibitionTherapeutic targeting of HER2-CB 2 R heteromers in HER2-positive breast cancer Activation of the orphan receptor GPR55 by lysophosphatidylinositol promotes metastasis in triple-negative breast cancerTargeting CB2-GPR55 receptor heteromers modulates cancer cell signalingSupport the show (https://www.paypal.com/paypalme/marybiles71)
Talk to a Dr. Berg Keto Consultant today and get the help you need on your journey (free consultation). Call 1-540-299-1557 with your questions about Keto, Intermittent Fasting, or the use of Dr. Berg products. Consultants are available Monday through Friday from 8 AM to 10 PM EST. Saturday & Sunday from 9 AM to 6 PM EST. USA Only. Take Dr. Berg's Free Keto Mini-Course! In this podcast, we're going to talk about the health benefits of selenium. What is selenium? Selenium is a trace mineral that has extremely powerful antioxidant properties. It's a co-factor enzyme, which means it's involved in a lot of different enzymes as a helper mineral. Its main job as an antioxidant is to help protect against oxidative damage. Selenium may be beneficial for chronic health problems and conditions where there is inflammation. Selenium benefits: 1. Helps make glutathione 2. Oxidative stress reduction 3. Required for the conversion of T4-T3 4. Reduced complications of certain diseases 5. Anticancer 6. Antitumor 7. It may be beneficial for those with alcohol-related liver disease 8. It may be beneficial for those with arsenic poisoning 9. It may be beneficial for those with autoimmune conditions 10. It may be beneficial for those with BPH 11. It may be beneficial for those with diabetes 12. It may help detox mercury The RDAs for selenium are 55mcg. But, the therapeutic dosage you may want to consider taking if you have any of the above conditions would be 200mcg. Selenium can have toxic effects if you take too much. Selenomethionine may be the most beneficial to take. Brazil nuts are one of the most selenium-rich foods. But, they are also very high in phytic acid. Phytic acid actually blocks selenium. If you want to consume Brazil nuts, be sure to soak them overnight and dry them out first to get rid of the phytic acid. DATA: https://bit.ly/3ftaSBO https://bit.ly/2AEUA9V https://bit.ly/2Bd500o Dr. Eric Berg DC Bio: Dr. Berg, 51 years of age is a chiropractor who specializes in weight loss through nutritional & natural methods. His private practice is located in Alexandria, Virginia. His clients include senior officials in the U.S. government & the Justice Department, ambassadors, medical doctors, high-level executives of prominent corporations, scientists, engineers, professors, and other clients from all walks of life. He is the author of The 7 Principles of Fat Burning. FACEBOOK: fb.me/DrEricBerg?utm_source=Podcast&utm_medium=Anchor TWITTER: http://twitter.com/DrBergDC?utm_source=Podcast&utm_medium=Post&utm_campaign=Daily%20Post YOUTUBE: http://www.youtube.com/user/drericberg123?utm_source=Podcast&utm_medium=Anchor DR. BERG'S SHOP: https://shop.drberg.com/?utm_source=Podcast&utm_medium=Anchor MESSENGER: https://www.messenger.com/t/drericberg?utm_source=Podcast&utm_medium=Anchor DR. BERG'S VIDEO BLOG: https://www.drberg.com/blog?utm_source=Podcast&utm_medium=Anchor
Consensus or Controversy? The Integration of Novel Therapies into the Interdisciplinary Management of Non-Small Cell Lung Cancer with CNS Metastases: Our most recent one-on-one interview with Dr Riely as a supplement to a CME symposium held during the 24th Annual Meeting and Education Day of the Society for Neuro-Oncology featuring expert comments on the application of emerging research to patient care. Improved treatment outcomes and impact on the incidence of brain metastases in patients with non-small cell lung cancer (NSCLC) (00:00) Case (Dr Gubens): A man in his mid-50s with adenocarcinoma of the lung with an EGFR exon 19 deletion mutation, asymptomatic brain lesions and significant systemic burden (03:43) Clinical care of patients with NSCLC brain metastases alone and no systemic disease (06:23) Diagnosis of radiation necrosis (11:42) Activity of the third-generation EGFR tyrosine kinase inhibitor (TKI) osimertinib in patients with NSCLC and CNS metastases (13:17) Mechanism of action of osimertinib in the brain and effect on CNS disease progression (15:43) Risks of whole-brain radiation therapy; role of hippocampus sparing and memantine administration in minimizing the adverse effects of whole-brain radiation therapy (17:42) Comparison of survival outcomes with stereotactic radiation therapy and EGFR TKIs (22:24) Case (Dr Gubens): A man in his late 40s with metastatic NSCLC with an ALK rearrangement and large asymptomatic brain metastases (24:46) Role of other TKIs (ie, BRAF, MET, HER2 inhibitors) in NSCLC with CNS metastases (28:15) Antitumor effect of ALK inhibitors in patients with CNS metastases (31:58) Practical issues in the management of CNS metastases: edema, symptomatic CNS metastases and oligoprogression (33:21) Managing CNS metastases with leptomeningeal involvement (36:44) Case (Dr Gubens): A man in his early 40s with metastatic adenocarcinoma of the lung with an EGFR L858R mutation responds to first-line osimertinib for 2 years but then develops 2 new asymptomatic punctate parenchymal metastases and extensive leptomeningeal involvement (39:01) Symptoms of CNS metastases with leptomeningeal involvement; challenges in diagnosis (43:13) Case (Dr Gubens): A woman in her late 60s with metastatic adenocarcinoma of the lung, no targetable tumor mutations and a PD-L1 tumor proportion score (TPS) of 80% (44:53) Outlook on the use of TKIs for patients with CNS metastases (48:42) Potential for combining TKIs with chemotherapy in the management of CNS metastases (50:19) Activity and safety of EGFR TKIs in combination with anti-PD-1/PD-L1 antibodies (52:14) CME information and select publications
Host: Vincent Racaniello Guests: Nicholas Arpaia and Tal Danino Vincent meets up with Nick and Tal to explain how they engineered E. coli to lyse within tumors and deliver an antibody that causes tumor regression in mice. Links for this episode: Programmable bacteria induce tumor immunity (Nat Med) Synchronized cycles of bacterial lysis (Nature) TWiM Listener survey Subscribe to TWiM (free) on iTunes, Google Podcasts, Stitcher, Android, RSS, or by email. You can also listen on your mobile device with the Microbeworld app. Become a Patron of TWiM! Music used on TWiM is composed and performed by Ronald Jenkees and used with permission. Send your microbiology questions and comments to twim@microbe.tv
Mr. Tomc is the Vice President of Human Nutrition at CV Sciences. He is a recognized authority on dietary supplements, with twenty years of experience in the nutritional health industry. Formerly the Vice President of North American Herb and Spice, where he served for 10 years, in addition to his service as Global Educator for omega-3 market leader, Nordic Naturals, Mr. Tomc is known for his extensive print interviews and contributions to noted books on integrative medicine, as well as his 4,000 radio appearances. A renowned educator, Mr. Tomc recognizes CBD and its multiple mechanisms of action to support human health, and envisions a new category of dietary supplements derived from agricultural hemp. Topics: 2:35 - From Omega 3 to CBD 4:30 - Eicosanoids and endocannabiods 8:15 - Who is CV Sciences? 12:00 - Regulatory status of CBD and hemp 17:20 - Who is the US Hemp Roundtable 21:14 - Over-the-Counter CBD products 23:35 - Marijuana-dervied CBD 26:35 - Great efficacy w/ terpenes? 29:30 - Isolated CBD v. whole-spectrum CBD 40:00 - Sativex v. Dronabinol 41:00 - Toxicology & safety of hemp extracts 44:00 - GRAS designation 50:00 - NOAEL (No-observed-adverse-effect level) 54:00 - Rescheduling of CBD 60:00 - Regulatory status of CBD post-Epidiolex Studies mentioned in this podcast: Appraising the “entourage effect”: Antitumor action of a pure cannabinoid versus a botanical drug preparation in preclinical models of breast cancer Overcoming the Bell-Shaped Dose-Response of Cannabidiol by Using Cannabis Extract Enriched in Cannabidiol An Assessment of the Genotoxicity and Subchronic Toxicity of a Supercritical Fluid Extract of the Aerial Parts of Hemp
Ep. 315: The Scoop on Red Light and Infrared Therapy In this episode, Stacy and Sarah tackle red light and infrared therapy and whether it's true science or fake quackery! Click here to listen in iTunes If you enjoy the show, please review it in iTunes! The Paleo View (TPV), Episode 315: The Scoop on Red Light and Infrared Therapy Intro (0:00) News and Views (0:40) Stacy went to the lake (and the boats stayed on the roof!) and has finally learned to stand and paddle her board! Sarah's kids have been at school for almost a month and she now has a middle schooler! Cole turned 13, so Stacy now has a teenager! School starts for her this week! This week's podcast is sponsored by Joov! If you want to check out Joov's light therapy boxes, visit https://joovv.com/paleoview Joovv is the main consumer product on the market that optimizes all the variables needed to hit that therapeutic window. Many other products out there use dosages and power outputs that are too low to achieve benefits, don’t use the right wavelengths, or don’t target large enough areas of our bodies (or better yet, target our entire body!). New FDA-approved electrostatic-coated LEDs that deliver even more intensity and have passed rigorous 3rd-party testing. Brand new modular design that lets you build a full-body Joovv system now—OR over time. The cool thing is that you can start with just one Joovv, and add on to it over time. Sort of like legos for light therapy! Lastly, all Joovvs now come with a cool built-in Bluetooth control that’s compatible with their new app as well as multiple connected home devices like Alexa and Google Home. “Alexa, I want to Joovv for 10 minutes.” Sarah loves hers and wants to build a whole room of them to stand in! Question from Terri: "I am considering purchasing a Red Light Therapy device...I have read about the sweet spots and the NM needed to be beneficial. I don't want to waste any money, so.....are they effective, or just a fad? I am most interested in skin rejuvenation, surface capillaries, joint and muscle effects. Thank You. Sarah, I value your advice. There are so many scam artists "out there"....hard to know what to believe!!!" Sarah believes in red light therapy because it's so well supported by scientific research! Dates back to the 1960s, when we discovered that low-level laser light caused mouse hair to grow back more quickly and also stimulated wound healing By the 1970s, low-level lasers on humans treated non-healing skin ulcers. Research on this therapy has grown to include various skin benefits (including wrinkle reduction!), weight loss, oral health improvement, improved muscle recovery, better sleep quality, enhanced thyroid health, reduced joint pain and inflammation Super well researched: over 3,000 published clinical studies on light therapy, including over 200 of them double-blinded, randomized, and placebo-controlled (the gold standard!). How does it work? It excites chromophores in your mitochondria and stimulates the energy chemical ATP to form! Induces transcription factors that play role in: protein synthesis, cytokine modulation, cell proliferation growth factors (muscle recovery, tissue repair, collagen formation), angiogenesis, tissue oxygenation, Endogenous antioxidant enzymes (SOD, iNOS), Liver regeneration, inflammatory mediators (pro and anti), CNS health (increases bone-derived neurotrophic factor) Immune cells are strongly affected by red light therapy, Strongly anti-inflammatory, Improves wound healing, Reverses age-related immune dysfunction, Promotes “M1-related immunoregulation” (immune balancing), Antiviral immunity, Antitumor immunity (inhibits tumor growth in studies), Pathogeneisis of autoimmune disease Effects on fibroblasts (collagen-forming cells), enhances production of basic fibroblast growth factor, increases the proliferation, maturity, and motility of fibroblasts (a type of cell that produces collagen and extracellular matrix). Resulting increase in collagen production responsible for much of the skin and joint benefits. Red light also decreases joint pain! Studies have found it to be a good alternative to NSAIDs! A study found that using red light therapy decreases the amount of thyroid medication needed Red and near infrared light has been shown to boost collagen, smooth wrinkles, enhance tone, boost healing and skin regeneration, reducing inflammation and cellular necrosis, and even combating acne. It helps with vitiligo, psoriasis, scars, and more! Existing research has shown that wavelengths of 635 nm can significantly reduce overall body circumference measurements of regions that have been spot-treated, including the waist, thighs, upper arms, and hips (and, studies are increasingly showing that these effects remain in place long-term!). There is an ideal wavelength for red light therapy. The best absorption by our tissues peaks in the ranges of 660-670 nm and 830-850 nm Currently, Joovv is the main consumer product on the market that optimizes all the variables needed to hit that therapeutic window. Many other products out there use dosages and power outputs that are too low to achieve benefits, don’t use the right wavelengths, or don’t target large enough areas of our bodies (or better yet, target our entire body!). Go to https://joovv.com/paleoview to get yours today! Get your questions in! We want to hear from you! And there's no end to questions we can answer and topics we can address! Engage on social media! That's how we get feedback! Thank you for listening!
In this week’s weed news we talk about #BRASIL, #NEWJERSEYMMJ, #DRIVING, #PETESESSIONS, and the #ANTITUMORWelcome to Weekly Weed News 2.0 the Podcast with Kief Preston, where I bring you the week’s most important news about weed, medical marijuana, recreational marijuana, cannabis legalization and anything else to do with the good herb – all while smoking on some good!This show was created to raise awareness about cannabis-related issues and motivate people to do something to help the movement and make marijuana legalization a reality as soon as possible. There are so many people we can help and there’s so much money to be made, not to mention all the people locked up that shouldn’t be.“Take Action Today to Help Legalize Weed Tomorrow” -Kief PrestonSTART HERE: kiefpreston.com/Wanna GROW? Free GROW BIBLE – bit.ly/2podIAgGOT VAPE? VaporNation has the Firefly 2 and ALL the BeSt Brands & FREE SHIPPING - bit.ly/2Lmmec3If you enjoy my content please leave a comment, ask a question, like it, share it, and subscribe for more! It will help me grow my blog and motivate more people to stand up for cannabis and start enjoying its’ many benefits.Stay UP! -Kief▶ STEEMIT steemit.com/@kiefpreston.com▶ Pinterest – pinterest.com/kiefpreston▶ Youtube Channel – bit.ly/2GPQg64▶ Kief Preston’s Time-Tested Edibles Cookbook Series bit.ly/2EXIwAZ▶ My website KiefPreston.com▶ You can also support the cause by shopping on Amazon for ANYTHING you need using this link amzn.to/2GrxPogMore FIRE TRACKS from LMR & Mr Go Hard bit.ly/2plIWbe▶ Hear me on Smoke Radio here: bit.ly/2JTCgJw》》》Check out the Weekly Weed News 2.0 Podcast on Spreaker: bit.ly/2HjLf99 or on Itunes, Stitcher, Soundcloud, iHeartRadio AND nOw on Spotify!
In this week’s weed news we talk about #BRASIL, #NEWJERSEYMMJ, #DRIVING, #PETESESSIONS, and the #ANTITUMORWelcome to Weekly Weed News 2.0 the Podcast with Kief Preston, where I bring you the week’s most important news about weed, medical marijuana, recreational marijuana, cannabis legalization and anything else to do with the good herb – all while smoking on some good!This show was created to raise awareness about cannabis-related issues and motivate people to do something to help the movement and make marijuana legalization a reality as soon as possible. There are so many people we can help and there’s so much money to be made, not to mention all the people locked up that shouldn’t be.“Take Action Today to Help Legalize Weed Tomorrow” -Kief PrestonSTART HERE: kiefpreston.com/Wanna GROW? Free GROW BIBLE – bit.ly/2podIAgGOT VAPE? VaporNation has the Firefly 2 and ALL the BeSt Brands & FREE SHIPPING - bit.ly/2Lmmec3If you enjoy my content please leave a comment, ask a question, like it, share it, and subscribe for more! It will help me grow my blog and motivate more people to stand up for cannabis and start enjoying its’ many benefits.Stay UP! -Kief▶ STEEMIT steemit.com/@kiefpreston.com▶ Pinterest – pinterest.com/kiefpreston▶ Youtube Channel – bit.ly/2GPQg64▶ Kief Preston’s Time-Tested Edibles Cookbook Series bit.ly/2EXIwAZ▶ My website KiefPreston.com▶ You can also support the cause by shopping on Amazon for ANYTHING you need using this link amzn.to/2GrxPogMore FIRE TRACKS from LMR & Mr Go Hard bit.ly/2plIWbe▶ Hear me on Smoke Radio here: bit.ly/2JTCgJw》》》Check out the Weekly Weed News 2.0 Podcast on Spreaker: bit.ly/2HjLf99 or on Itunes, Stitcher, Soundcloud, iHeartRadio AND nOw on Spotify!
Design of a synchronously lysing bacterium for delivery of anti-tumor molecules in mice, and hopanoids, the lipids that live forever, brought to you by the four Microbies of TWiM. Hosts: Vincent Racaniello, Elio Schaechter, Michael Schmidt, and Michele Swanson. Subscribe to TWiM (free) on iTunes, Stitcher, RSS, or by email. You can also listen on your mobile device with the Microbeworld app. Links for this episode Bacterial lysis for in vivo delivery (Nature) Coley’s toxins (Iowa Orthop J) Hopanoids, stress tolerance, and nutrient storage (Geobiol) Lipids that last forever (STC) Fattening up microbial geological biomarkers (STC) Money spreads infection (Fut Micro) This episode is brought to you by CuriosityStream, a subscription streaming service that offers over 1,400 documentaries and nonfiction series from the world's best filmmakers. Get unlimited access starting at just $2.99 a month, and for our audience, the first two months are completely free if you sign up at curiositystream.com/microbe and use the promo code MICROBE. This episode is also brought to you by Drobo, a family of safe, expandable, yet simple to use storage arrays. Drobos are designed to protect your important data forever. Visit www.drobo.com to learn more. Listeners can save $100 on a Drobo system at drobostore.com by using the discount code Microbe100. Send your microbiology questions and comments (email or mp3 file) to twim@microbe.tv
Background To overcome the limitations of animal-based experiments, 3D culture models mimicking the tumor microenvironment in vivo are gaining attention. Herein, we investigated an alginate-based 3D scaffold for screening of 5-fluorouracil (5-FU) or/and curcumin on malignancy of colorectal cancer cells (CRC). Methods The potentiation effects of curcumin on 5-FU against proliferation and metastasis of HCT116 cell and its corresponding isogenic 5-FU-chemoresistant cells (HCT116R) were examined in a 3D-alginate tumor model. Results CRC cells encapsulated in alginate were able to proliferate in 3D-colonospheres in a vivo-like phenotype and invaded from alginate. During cultivation of cells in alginate, we could isolate 3 stages of cells, (1) alginate proliferating (2) invasive and (3) adherent cells. Tumor-promoting factors (CXCR4, MMP-9, NF-κB) were significantly increased in the proliferating and invasive compared to the adherent cells, however HCT116R cells overexpressed factors in comparison to the parental HCT116, suggesting an increase in malignancy behavior. In alginate, curcumin potentiated 5-FU-induced decreased capacity for proliferation, invasion and increased more sensitivity to 5-FU of HCT116R compared to the HCT116 cells. IC50 for HCT116 to 5-FU was 8nM, but co-treatment with 5 μM curcumin significantly reduced 5-FU concentrations in HCT116 and HCT116R cells (0.8nM, 0.1nM, respectively) and these effects were accompanied by down-regulation of NF-κB activation and NF-κB-regulated gene products. Conclusions Our results demonstrate that the alginate provides an excellent tumor microenvironment and indicate that curcumin potentiates and chemosensitizes HCT116R cells to 5-FU-based chemotherapy that may be useful for the treatment of CRC and to overcome drug resistance.
Medizinische Fakultät - Digitale Hochschulschriften der LMU - Teil 05/19
Thu, 8 Dec 2005 12:00:00 +0100 https://edoc.ub.uni-muenchen.de/4938/ https://edoc.ub.uni-muenchen.de/4938/1/Adam_Christian.pdf Adam, Christian ddc:61
Randomized trials performed in anthracycline-pretreated breast cancer patients have demonstrated good activity of taxane-based regimens. In a face to face comparison, single-agent docetaxel proved to be significantly more effective than paclitaxel. Treatment with docetaxel was also associated with an increased incidence of grade grade-3/4 toxicities in this trial. Antitumor activity of taxane-based combination regimens was clearly superior to single-agent therapy in two trials. As anticipated, treatment-associated toxicity was greater with combination regimens, but this did not affect quality of life.
© 2020-2025 Ivy Podcast Discovery LLC
